welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals announces last patient completes phase 3 trial protocol of CPP-1X/sul for familial adenomatous polyposis
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today the last patient has completed the study protocol in its pivotal Phase 3 trial of CPP-1X/sul for adults with familial adenomatous polyposis (FAP), a rare genetic disease that, if left untreated, progresses to colorectal cancer in nearly 100% of patients.
Analysis of the results from the randomized, double-blind trial are expected to be complete in early 2019, followed by potential submission of a New Drug Application (NDA) with the US Food and Drug Administration (FDA), which has granted CPP-1X/sul for the treatment of FAP fast track and orphan drug designation.
“Patients currently suffering from FAP have no effective treatments to delay or prevent progression of their disease,” said Carol A. Burke, MD, a gastroenterologist at the Cleveland Clinic and principal investigator for the FAP-310 clinical trial.
expertly curated content related to this topic
-
Long Term Treatment with Sulindac in Familial Adenomatous Polyposis: Is there an Actual Efficiacy in Prevention of ...BACKGROUND AND OBJECTIVES : Ileorectal a...
-
Primary Chemoprevention of Familial Adenomatous Polyposis with SulindacBACKGROUND : Familial adenomatous polypo...
-
Chemoprevention of Familial Adenomatous PolyposisFamilial adenomatous polyposis (FAP) has...
-
The Effects of Sulindac on the Pathology of Colorectal Remnant Polyps of Familial Adenomatous Polyposis (FAP) Patien...OBJECTIVE : To evaluate the long-term ef...
-
Chemoprevention in Familial Adenomatous PolyposisFamilial adenomatous polyposis (FAP) pre...
-
New treatment reduces precancerous polyps in hereditary cancer patientsInheriting a mutation in the APC gene le...